Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial.
Quick navigation
Link to full study
http://www.ncbi.nlm.nih.gov/pubmed/21775755
Conclusion of this study
Four-year treatment with ALA in mild-to-moderate DSPN did not influence the primary composite end point but resulted in a clinically meaningful improvement and prevention of progression of neuropathic impairments and was well tolerated. Because the primary composite end point did not deteriorate significantly in placebo-treated subjects, secondary prevention of its progression by ALA according to the trial design was not feasible.
Supplements analyzed in this study
Health conditions analyzed in this study
Functions related to this study
Body systems related to this study